A phase II study of HFNC in advanced cancer patients with dyspnea and poor PS
Phase 2
- Conditions
- advanced cancer
- Registration Number
- JPRN-UMIN000035738
- Lead Sponsor
- Wakayama Medical University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 24
Inclusion Criteria
Not provided
Exclusion Criteria
1. Patients who need 8 or more opioid rescue use per day. 2. Patients who plan artificial respiration management. 3. Patients who already have used HFNC. 4. Patients who have disturbance of consciousness of 12 or less GCS. 5. Patients under sustained sedation. 6. Patients with cognitive impairment or mental disorder who are regarded as inadequate to evaluate for the study by the investigators. 7. Patients who have participated in the other study at the time of the informed consent, or will participate in the other study. 8. Any other cases who are regarded as inadequate for the study enrollment by the investigators.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Change amount of modified Borg scale at the start of treatment 24hours
- Secondary Outcome Measures
Name Time Method 1. Change amount of modified Borg scale 2. Change amount of comfort(Numerical Rating Scale) 3. Respiratory rate 4. Implementention rate of medical therapy 5. SpO2 6. Glassgow Coma Scale 7. Completion rate of treatment